Health care stocks were mixed pre-bell Thursday, with The Health Care Select Sector SPDR Fund (XLV) marginally lower and the iShares Biotechnology ETF (IBB) up 0.5%.
UnitedHealth Group (UNH) is facing a criminal investigation by the US Department of Justice over possible Medicare fraud tied to its Medicare Advantage operations, The Wall Street Journal reported, citing people familiar with the matter. The company's shares were down past 8% premarket.
Biohaven (BHVN) stock was more than 11% lower after the company said Wednesday that the US Food and Drug Administration's Office of Neuroscience is extending the Prescription Drug User Fee Act, or PDUFA, date for troriluzole's new drug application for the treatment of spinocerebellar ataxia by three months.
Mesoblast (MESO) shares were up over 7% after the company said overnight it received seven years of orphan drug exclusivity from the US Food and Drug Administration for Ryoncil, a treatment approved for steroid-refractory acute graft versus host disease in children aged two months and older.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。